Venus Remedies Limited
Financial trend (100/100) does the heavy lifting; momentum (38/100) is the drag.
Buy zoneVenus Remedies Limited earns a Strong Buy from StocksWizard, with a blended score of 78/100. At ₹1,616.3 it trades below our blended DCF and relative-multiples fair value of ₹2,700.96, about 67% upside to that estimate — we read it as undervalued by 67%. On 19.0x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 16% below its 52-week high of ₹1,934.54 and 277% above the low of ₹428.54. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9. It clears 9 of 11 investability checks, with durability 75, valuation 83 and momentum 38 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹2,160.77.
1-year price
EOD · 2026-09-1452-week range
-16.45% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Strong Buy78Piotroski F-score 6/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- No data: ROE above 15%
- Pass: Low debt (D/E < 0.5): 0.02x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 36%
- Pass: Earnings growing: 139%
- Pass: Net margin ≥ 10%: 14.3%
- No data: Current ratio > 1.5
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 8.27
- Fail: Piotroski ≥ 7: 6/9
Shareholding
- Promoter48.6%
- Institutions1.2%
- Public & other50.2%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 8.27.
Opportunities
- Earnings growing (139% YoY).
- Revenue growing (36% YoY).
- Trading in our value buy zone versus sector peers.
- Trades ~67% below our estimated fair value.
About Venus Remedies Limited
Venus Remedies Limited operates as a pharmaceutical company in India and internationally, with research and development focused on antimicrobial resistance and oncology. The company manufactures and offers a broad range of medications including analgesics, antipyretics, antibiotics, anticoagulants, antiemetics, antivirals, cardiovascular drugs, disinfectants, antiseptics, gastrointestinal therapies, hepatoprotective agents, steroids, immunostimulating agents, iron supplements, and muscle relaxants.
Venus Remedies Limited — frequently asked questions
Is Venus Remedies Limited a buy, hold or sell?
StocksWizard currently rates Venus Remedies Limited (VENUSREM) a Strong Buy, based on a blended score of 78/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Venus Remedies Limited's fair value?
Our blended DCF and relative-valuation model estimates Venus Remedies Limited's fair value at about ₹2,700.96, versus a current price of ₹1,616.3 — roughly 67% upside. On that basis the stock looks undervalued by 67%.
Is Venus Remedies Limited financially healthy?
Venus Remedies Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9.
How has Venus Remedies Limited's share price performed?
Venus Remedies Limited is down 14% over three months, and last traded at ₹1,616.3. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.